RDTI 10-year cap threatens biotech sector; AusBiotech urges review
RDTI 10-year cap threatens biotech sector; AusBiotech urges review
16 articlesWhy it matters
Policy shifts in RDTI and Medicare-related rules shape how health tech and biotech raise and deploy capital. The changes tilt advantage toward larger, adaptive players while increasing uncertainty for startups and digital health vendors.
Methodology: This digest condenses the source coverage listed below for faster scanning by Australian health teams. It is not medical advice.
RDTI 10-year cap threatens biotech sector; AusBiotech urges urgent policy review.
The signatories argue that a decade-long cap would complicate bringing long development medicines and devices to patients, potentially deterring investment in downstream, high-impact innovations. Established firms that can navigate policy changes gain an edge, while digital and connected-health developers face stricter eligibility and more uncertainty. The decision now hinges on a timely policy review that aligns incentives with real development timelines.
From July 1, 2026, bulk-billing claims must be supported by a valid Assignment of Benefit captured before submission. Front-desk workflows face tighter compliance as practice management software vendors and payment platforms align to the new rules. Winners include PMS vendors offering native AoB capture; losers are clinics still running on paper or fragmented processes. The shift raises the risk of Medicare fraud exposure and could influence how payroll tax concessions are applied, depending on retention arrangements.
OAIC ACAPS 2026 reports rising privacy concerns, with 87 per cent more Australians worried than five years ago and a 73 per cent rise in complaints this year. Trust in AI remains very low at 4 per cent, even as trust in health service providers stays relatively high. Health tech operators that demonstrate transparent data handling and solid consent management can advance adoption, while ungoverned AI tools risk slow uptake or rejection.
Since July 2025 the National Lung Cancer Screening Program has enrolled more than 90,000 people into LDCT screening, with GPs central to identifying eligible individuals. Eligibility includes age 50–70, heavy smoking history, and current or recent quit within a decade, with management under the National Cancer Screening Register for invitations and follow-ups. The winners are primary care networks gaining a clearer, data-backed path to enrol eligible patients; the risk is inconsistent CIS integration across clinics that hampers uniform uptake and timely follow-up.